NEAL ANTHONY SCOTT, M.D., Ph.D. Curriculum Vitae PROFESSIONAL ADDRESS: Peninsula Cardiovascular, Inc. 2490 Hospital Drive, Suite 212 Mountain View, CA 94040 Telephone: (650) 962-4460 EDUCATION: 1971-1975 B.S., Stanford University, Stanford, CA (Chemistry) 1975-1982 Ph.D., Massachusetts Institute of Technology, Cambridge, MA (Neural and Endocrine Regulation) 1975-1982 M.D., Harvard Medical School, Boston, MA POSTGRADUATE TRAINING: 1982-1983 1983-1985 1985-1989 1986-1989 1989-1990 Intern, Internal Medicine, Univ. of California, San Diego Resident, Internal Medicine, Univ. of California, San Diego Fellow in Cardiology, Stanford University, Stanford, CA Postdoctoral Research Fellow, UC San Diego Fellow in Coronary Interventions, Emory University Medical Center, Atlanta, GA WORK HISTORY: 2006- Cardiologist in Private Practice 2000-2006 Founder, Vice-President, Medical Director, Medluminal Systems, Inc. 1998-2001 Associate Professor, Emory University School of Medicine, Atlanta, GA 1990-1998 Assistant Professor, Emory University School of Medicine, Atlanta, GA ACADEMIC APPOINTMENTS: Primary Appointments: 1 1998-2001 1990-1998 Associate Professor, Emory University School of Medicine, Atlanta, GA Assistant Professor, Emory University School of Medicine, Atlanta, GA Secondary Appointments: 1986 – 1989 1990 - 2001 Clinical Instructor, Stanford University, Stanford, CA Collaborative Scientist, Yerkes Regional Primate Center, Atlanta, GA CLINICAL APPOINTMENTS: 1986 – 1989 1987 – 1989 1990 – 2001 1990 – 2001 1990 – 1994 1990 – 1994 1994 - 2001 2002 2005 2006 2009 - Instructor, Dept of Surgery (Emergency Dept. and Life Flight Attending), Stanford University Life Flight Attending, UC San Diego Cardiology Attending, Emory University Hospital, Atlanta, GA Cardiology and Internal Medicine Attending, Grady Memorial Hospital, Atlanta, GA Cardiology Attending, Atlanta Veterans Administration Hospital, Atlanta, GA Member, The Emory Clinic, Atlanta, GA Senior Member, The Emory Clinic, Atlanta, GA Cardiologist, El Camino Hospital, Mountain View, CA Cardiologist, O’Connor Hospital, San Jose, CA Cardiology Attending, Palo Alto Veterans Administration Hospital, Palo Alto, CA Cardiology Attending, Stanford University Medical Center, Stanford, CA LICENSURES: 1989 - 2003 1984 - 1990 2002 - Licensed Physician, State of Georgia, #032048 (expired) Licensed Physician, State of California, #G52828 Licensed Physician, State of California, #G52828 BOARD CERTIFICATIONS: 2010 1999 1989 1985 1984 Interventional Cardiology, American Board of Internal Medicine, Certificate # 105904 (Re-certification) Interventional Cardiology, American Board of Internal Medicine, Certificate # 105904 Cardiovascular Diseases, American Board of Internal Medicine, Certificate # 105904 Internal Medicine, American Board of Internal Medicine, Certificate # 105904 Diplomate, National Board of Medical Examiners, Certificate # 211275 2 COMMITTEE MEMBERSHIPS: National: 1995 - 2000 Data Safety and Monitoring Committee (NIH): The SHOCK Trial Regional and State: 1992 - 1995 1993 - 2000 1998 - 2000 Research Peer Review Committee, American Heart Assoc, Georgia Affiliate Board of Directors, American Heart Association, (DeKalb County Branch) Medical Director, American Heart Association, (Dekalb County Branch) Institutional: 1993 - 2000 1997- 1998 Emory Medical School Admissions Committee (Associate Member), Human Resources Committee (Emory Clinic) INDUSTRY EXPERIENCE: Founder, XRT Corporation, St. Paul, MN, 1994 Medical Director, XRT Corporation, 1996 – 1998 XRT developed a catheter with an X-ray generator at its tip for use in coronary and peripheral arteries. The company was acquired by Medtronic Inc. in 2000 Founder, Medluminal Systems, Inc., Palo Alto, CA 2000 Vice President and Medical Director, Medluminal Systems, 2000-2006 Medluminal Systems developed drug delivery catheters for coronary and peripheral vascular indications. The intellectual property for these devices was acquired by Boston Scientific Corp. in 2006. Consultant, CardioMind, Inc., Sunnyvale, CA 2005 - 2010 CardioMind has developed a guidewire-based stent delivery system for coronary and peripheral indications. CardioMind was acquired by Biosensors International in 2010. 3 MANUSCRIPT REVIEWER: Ad Hoc Reviewer: Circulation Journal of the American College of Cardiology American Journal of Cardiology Catheterization and Cardiovascular Interventions Coronary Artery Disease American Heart Journal American Journal of Medical Sciences AWARDS AND HONORS 1992-1994 1987-1989 1982 1979-1981 Robert Wood Johnson Foundation Fellowship Robert Wood Johnson Foundation Fellowship Kaiser Merit Fellowship (Harvard Medical School) Whitaker Health Sciences Fellowship (Massachusetts Institute of Technology) Sandoz Foundation Fellowship (Massachusetts Institute of Technology) SOCIETY MEMBERSHIPS: 1993 1993 - 2000 1991 1983 - 2000 Fellow, American College of Cardiology Member, Society for Cardiac Angiography and Interventions Member, American Heart Association Member, American Federation of Clinical Research ORGANIZATION OF NATIONAL OR INTERNATIONAL CONFERENCES: SESSIONS AS CHAIRMAN: 1991 American Heart Association Scientific Sessions; "Coronary Atherectomy". 1993 American College of Cardiology; "Restenosis Animal Models". 1994 American College of Cardiology; "Local Delivery" and "Basic Mechanisms in Restenosis". 1995 American College of Cardiology; "Local Intracoronary Delivery". 4 1995 American Heart Association Scientific Sessions; “Intracoronary Ultrasound and Doppler”. 1998 American College of Cardiology; “Late-breaking Clinical Trials”. 1998 American Heart Association Scientific Sessions; “Intracoronary Radiation”. PATENTS: ISSUED: Boublik JH, Rivier JEF, Brown MR, Scott NA: NPY Peptide Analogs. U.S. Patent Number: 5,026,685. Issued: June 25, 1991. Boublik JH, Rivier JEF, Brown MR, Scott NA: NPY Peptide Analogs. U.S. Patent Number: 5,328,899. Issued: Jul. 12, 1994 Scott NA, Hanson SR, King SB III, Harker LA. Stent sheath for local drug delivery. U.S. Patent Number 5,383,928. Issued: January 24, 1995. Hanson SR, Scott NA, King SB III, Harker LA. A device for local drug delivery and methods for using the same. U.S. Patent Number 5,523,092. Issued: June 4, 1996. Hanson SR, Scott NA, King SB III, Harker LA. A device for local drug delivery and methods for using the same. U.S. Patent Number 5,709,874. Issued: January 20, 1998. Hanson SR, Scott NA, Markou C, King SB III. Device and method for nonocclusive localized drug delivery. U.S. Patent Number 5,985,307. Issued: November 16, 1999. Waksman R, King SB, Scott NA. Endovascular support device and method of use. U. S. Patent Number 6,355,055. Issued: March 12, 2002. Hampikian JM, Scott NA. Radioactive coating solutions, methods and substrates. US Patent Number 6,475,644 B1. Issued: November 5, 2002 Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent at a site of treatment. US Patent Number 7,292,885. Issued: November 6, 2007. 5 Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,488,313. Issued: February 10, 2009 Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,488,314. Issued: February 10, 2009 Scott NA, Segal J, Shih LB, Harris S, Burkoth T. Polymer coated device for electrically mediated drug delivery. US Patent Number 7,517,342. Issued: April 14, 2009. Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Number 7,519,418. Issued: April 14, 2009. PENDING (published): Scott NA, King SB III. Catheter and method for ostial stent placement (European Union Patent Application). Scott NA, Hampikian JM. Bachytherapy device and method of use. US Patent Application # 20030092957. Segal J, Hampikian JM, Scott NA. Device and method for dilating and irradiating a vascular segment or body passageway. US Patent Application # 20020077520. Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent at a site of treatment. US Patent Application # 20030100886. Scott NA, Segal J. Mechanical apparatus and method for dilating and delivering a therapeutic agent at a site of treatment. US Patent Application # 20030100887. Scott NA, Segal J. Charged liposomes or micelles with encapsulated medical compounds. US Patent Application # 20040034336. Scott NA, Segal J, Burkoth T, Harris S. High concentration medicament and polymer coated device for passive diffusional drug delivery. US Patent Application # 2005/0159704. 6 Segal J, Scott NA. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment. US Patent Application #2005/0054978. GRANT SUPPORT: NIH Sponsored Grants: Small Business Innovative Research (SBIR) Award): “Prevention of Restenosis with a Novel Radiation Catheter” 8/2001 – 3/2002 (1R43 CA88636-01A1; Principal Investigator: N.A. Scott) 5 RO1 HL47838 NIH/NHLBI: (co-investigator); (Principal Investigator: J.N. Wilcox) “Thrombosis and Vascular Lesion Formation”, 9/91 - 7/96 1 RO1 HL49743 NIH/NHLBI: (co-investigator); (Principal Investigator: J.N. Wilcox) “Biological Mediators of Atherogenesis in Black Americans”, 9/92 9/96 Other: Georgia Research Alliance (Faculty Research Commercialization Program): “A Catheter for Intracoronary Radiation” 7/98 – 6/99; (Principal Investigator: N.A. Scott) Georgia AHA Grant-in-Aid: (Principal Investigator: N.A. Scott) “Restenosis: Mechanisms and Management”, 7/96 - 6/98 7 MANUSCRIPTS: 1. Scott NA, DeSilva RA, Lown B, Wurtman RJ. Tyrosine administration decreases vulnerability to ventricular fibrillation in the normal canine heart. Science 211:727-729, 1981. 2. Reinstein DK, Lehnert H, Scott NA, Wurtman RJ. Tyrosine prevents behavioral and neurochemical correlates of an acute stress in rats. Life Sciences 34:22252231, 1984. 3. Maisel AS, Scott NA, Gilpin E, Ahnve S, LeWinter M, Henning H, Collins D, Ross J. Complex ventricular arrhythmias in Qwave versus non-Q-wave myocardial infarction. Circulation 72:963-970, 1985. 4. Scott NA, Webb V, Boublik JH, Rivier J, Brown M. The cardiovascular actions of centrally administered Neuropeptide Y. Regulatory Peptides 25: 247258,1989. 5. Boublik JH, Scott NA, Brown MR, Rivier J. Structure-activity relationships of D-substituted and N-terminally modified analogs and C- and N- terminal fragments of neuropeptide Y. J Med Chem 32:597-601, 1989. 6. Maisel AS, Scott NA, Motulsky HJ, Ziegler M, Brown MR. Elevation of Neuropeptide Y in congestive heart failure. Am J Med 86:43-48, 1989. 7. Boublik JH, Scott NA, Taulane J, Goodman M, Brown M, Rivier J. Neuropeptide Y and Neuropeptide Y 18-36; structural and biological characterization. Intl J Pept Prot Res 33:11-15,1989. 8. Scott NA, Michel MC, Boublik JH, Rivier JE, Motomura S, Crum RL, Landon M, Brown MR. Distinction of NPY receptors in vitro and in vivo II. Differential effects of NPY and NPY-(18-36). Am J Physiol 259:H174-H180, 1990. 9. Boublik JH, Spicer MA, Scott NA, Brown MR, Rivier JE. Biologically active Neuropeptide Y analogs. Ann NY Acad Sci 611:27-34,1990. 10. Allen RA, Boublik J, Hauger RL, Scott N, Rivier J, Brown MR. Neuropeptide Y radioimmunoassay: characterization and application. Clinical and Experimental Pharmacology and Physiology 18: 825-833, 1991. 11. Feinstein RD, Boublik JH, Kirby D, Spicer MA, Craig AG, Malewicz K, Scott NA, Brown MR, Rivier JE. Structural requirements for Neuropeptide Y18-36 evoked hypotension: a systematic study. J Med Chem 35: 2836-2843, 1992. 8 12. Segal J, Kern MJ, Scott NA, King SB 3rd, Doucette JW, Heuser RR, Offili E, Siegel R. Alterations of phasic coronary artery flow velocity in humans during percutaneous coronary angioplasty. J Am Coll Cardiol 20: 276-286, 1992. 13. Scott NA, King SB 3rd. Coronary stents. Coronary Artery Dis 3:901-907, 1992. 14. Scott NA, Weintraub WS, Carlin SF, Tao X, Douglas JS Jr, Lembo NJ, King SB 3rd. Recent changes in the management of acute closure during coronary angioplasty. Am J Cardiol 71:1159-1163, 1993. 15. Vyavahare N, Scott NA, Hanson SR, Kohn J. In vitro and in vivo evaluation of the site specific administration of d-phenylalanyl-l-prolyl-l-arginyl chloromethyl ketone (PPACK) - a powerful thrombin inhibitor. Journal of Controlled Release 27:165-173,1993. 16. Scott NA, Kelsey SF, Detre K, Cowley MJ, King SB 3rd, and the NHLBI PTCA Registry Investigators. Percutaneous Transluminal Coronary Angioplasty in African-Americans: an analysis of the National Heart, Lung and Blood Institute PTCA Registry. Amer J Cardiol 73:1141-1146, 1994. 17. Scott NA, Pettigrew RI. Absence of movement of coronary stents after placement in a magnetic resonance imaging field. Amer J Cardiol 73:900-901, 1994. 18. Nunes GL, Hanson SR, King SB 3rd, Sahatjian RA, Scott NA. Local delivery of an antithrombin with a hydrogel-coated PTCA balloon catheter inhibits plateletdependent thrombosis. J Amer Coll Cardiol 23: 1578-1583, 1994. 19. Waksman R, Ghazzal ZMB, Scott NA, Douglas JS Jr, King SB 3rd. Efficacy and safety of using perfusion dilatation catheter as initial balloon in coronary angioplasty. Catheter Cardiovasc Diagnosis 32:319-322, 1994. 20. Scott NA, Nunes GL, King SB 3rd, Harker LA, Hanson SR. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation 90:1951-1955, 1994. 21. Robinson KA, Candal FJ, Scott NA, Ades EW. Seeding of vascular grafts with an immortalized human dermal microvascular endothelial cell line. Angiology 46:107-13, 1995. 22. Waksman R, Douglas JS Jr, Scott NA, Ghazzal ZM. Yee-Peterson J, King SB 3rd. Distal embolization is common after directional atherectomy in coronary arteries and saphenous vein grafts. Amer Heart Journal 129:430-5, 1995. 9 23. Scott NA, Thomas CN, Nunes GL, Robinson KA, Rowland SM, Juman I, Harker LA, King SB 3rd, Hanson SR. A comparison of the thrombogenicity of stainless steel and tantalum coronary stents. Amer Heart Journal 129:866-72, 1995. 24. Scott NA, Candal FJ, Robinson KA, Ades EW. Seeding of intracoronary stents with immortalized human microvascular endothelial cells. Amer Heart Journal 129:860-66, 1995. 25. Scott NA. Current status and potential applications of drug delivery balloon catheters. J Interventional Cardiology 8:406-419, 1995. 26. Scott NA, McManamon R, Strobert E, Cipolla G, Tarazona N, Swenson RB. Invivo diagnosis of coronary artery disease in a gorilla. J Zoo and Wildlife Med 26:139-143, 1995. 27. Nunes GL, Thomas CN, Hanson SR, Barry JJ, King SB 3rd, Scott NA. Local delivery of heparin via a hydrogel-coated PTCA balloon catheter inhibits plateletdependent thrombosis. Circulation 92:1697-1700, 1995. 28. Thomas CN, Weintraub WS, Shen Y, Ghazzal ZMB, Douglas JS Jr, King SB 3rd, Scott NA. Bailout coronary stenting in patients with a recent myocardial infarction. Amer J Cardiol 77: 653-655, 1996. 29. Waksman R, Scott NA, Ghazzal ZMB, Mays R, Frerichs FA, Petersen JY, King SB 3rd. A randomized comparison of flexible versus non-flexible femoral sheaths on patient comfort after angioplasty. Amer Heart Journal 131: 10761078, 1996. 30. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin F, Simonet L, Wilcox JN. Potential role of the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation 93: 2178-2187, 1996. 31. Wilcox JN, Scott NA. Potential role of the adventitia in arteritis and atherosclerosis. International J Cardiol 54: (Suppl.) S21-S35, 1996. 32. Thomas CN, Robinson KA, Cipolla GL, King SB 3rd, Scott NA. Local intracoronary delivery of heparin with a microporous balloon catheter. Amer Heart Journal 132: 969-972, 1996. 33. Wilcox JN, Waksman R, King SB 3rd, Scott NA. The role of the adventitia in the arterial response to angioplasty. International Journal of Radiation Oncology, Biology, Physics 36: 789- 796, 1996. 34. Jones SA, Leclerc H, Chatzimavroudis GP, Kim YH, Scott NA, Yoganathan AP. The influence of acoustic impedance mismatch on post-stenotic pulsed-doppler 10 ultrasound measurements in a coronary artery model. Ultrasound in Medicine & Biology 22: 623-34, 1996. 35. Wilcox JN, Cipolla GD, Martin FH, Simonet L, Dunn B, Ross CE, Scott NA. Contribution of adventitial myofibroblasts to vascular remodeling and lesion formation after experimental angioplasty in pig coronary arteries. Ann NY Acad Sci 811:437-47, 1997. 36. De Leon H, Scott NA, Martin F, Simonet L, Bernstein KE, Wilcox JN. Expression of nonmuscle myosin heavy chain-B isoform in the vessel wall of porcine coronary arteries after balloon angioplasty. Circulation Research 80:514519, 1997. 37. Waksman R, Rodriguez JC, Robinson KA, Cipolla GD, Crocker IR, Scott NA, King SB 3rd, Wilcox JN. Effect of intravascular irradiation on cell proliferation, apoptosis and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation 96:1944-1952, 1997. 38. Waksman R, Weintraub WS, Ghazzal ZMB, Scott NA, Shen Y, King SB 3rd, Douglas JS Jr. Acute and long-term outcome of narrowed saphenous vein bypass graft. A comparison of treatment with Palmaz-Schatz stent, directional coronary atherectomy and balloon angioplasty. Amer Heart J 134(2 Pt 1):274-81, 1997. 39. Viel K, Cui J, Thomas CN, Nunes GL, Cipolla G, King SB 3rd, Scott NA. Inhibition of platelet deposition with local delivery of heparin using a double balloon catheter. Thrombosis Research 88:147-157, 1997. 40. Scott NA. Hyperlipidemia in African-Americans. ABC Digest of Urban Cardiology 4:17-22, 1997. 41. Scott NA, Wilcox JN. Role of the adventitial vasculature in resteonsis: a new view of an old problem. J Amer Coll Cardiol 32 (7): 2080, 1998. 42. Levy D, Merz CNB, Cody RJ, Fouad-Tarazi FM, Francis CK, Pfeffer MA, Scott NA, Swan HJC, Taylor MP, Weinberger MH. Hypertension detection, treatment and control. A call to action for cardiovascular specialists. J Amer Coll Cardiol 34:1360-1361, 1999. 43. Scott NA. The soft x-ray catheter system. Current Interventional Cardiology Reports 1:48-50, 1999 44. Scott NA, Crocker IR, Yin QQ, Sorescu D, Wilcox JN, Griendling KK. Inhibition of vascular cell growth by x-ray irradiation: comparison with gamma radiation and mechanism of action. Inter J Radiation Oncology, Biology and Physics 50:485-493, 2001. 11 45. Garas SM, Huber P, Scott NA. Overview of therapeutics for prevention of restenosis after coronary interventions. Pharmacology and Therapeutics 92 (23):165-78, 2001. 46. Okamoto E, Couse T, De Leon H, Vinten-Johansen J, Goodman RB, Scott NA, Wilcox JN. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104: 2228-35, 2001. 47. Scott NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury Advanced Drug Delivery Reviews 3: 358-376, 2006. MONOGRAPHS: Scott NA, editor. Cardiovascular Disorders in African Americans, Physicians Press, Birmingham, MI, 1997. CHAPTERS: 1. Brown MR, Scott NA, Boublik J, Allen RS, Ehlers R, Landon M, Crum R, Ward D, Bronsther O, Maisel A, Rivier J. Neuropeptide Y: Biological and clinical studies. In: Neuropeptide Y, V. Mutt, K. Fuxe, T. Hokfelt, J.M. Lundberg (eds), Raven Press, New York, 1989, pp 321-329. 2. Boublik JH, Spicer MA, Scott NA, Rivier JE, Brown MR. High dose Neuropeptide Y elicits biphasic effects on the conscious rat cardiovasculature: structure-activity studies. In: Maggi M, ed., Horizons in Endocrinology; Raven Press: New York, 1991; Vol II, pp 229-234. 3. Scott NA, Gravanis MB. Heart Failure. In: Cardiovascular Disorders: Pathogenesis and Pathophysiology, Gravanis MB, ed., Mosby - Yearbook, Inc., St. Louis, MO, 1993. 4. Wilcox JN, Waksman R, King SB 3rd, Scott NA. The role of the adventitia in the arterial response to angioplasty. In: Vascular Brachytherapy, Waksman R, King SB, Crocker IR, Mould RF, eds. Nucleotron, Veenendaal, Netherlands, 1996. 5. Scott NA. Photodynamic therapy. In: Vascular Brachytherapy, Waksman R, King SB, Crocker IR, Mould RF, eds. Nucleotron, Veenendaal, Netherlands, 1996. 6. Scott NA. Intracoronary Stents. In: Atlas of Heart Diseases, Interventional Cardiology, Volume XIII, King SB III, Douglas JS Jr, ed., Current Medicine, Philadelphia, PA; pp 7.1-7.20; 1997. 12 7. Scott NA. Other Devices. In: Atlas of Heart Diseases, Interventional Cardiology, Volume XIII, King SB III, Douglas JS Jr, ed., Current Medicine, Philadelphia, PA; pp 8.1-8.9; 1997. 8. Scott NA. Hypertension in African Americans. In: Cardiovascular Disorders in African Americans, Scott NA, editor. Physicians Press, Birmingham, MI, 1997. 9. Scott NA. Lipid Abnormalities in African Americans. In: Cardiovascular Disorders in African Americans, Scott NA, editor. Physicians Press, Birmingham, MI, 1997. 10. Scott NA. Coronary Disease in African Americans. In: Cardiovascular Disorders in African Americans, Scott NA, editor. Physicians Press, Birmingham, MI, 1997. 11. Wilcox JN, Scott NA. Adventitial remodeling associated with post-angioplasty restenosis. In: Vascular Brachytherapy, 2nd edition, pp21-30 Futura Publishing Co., Aramonk, NY, 1999. 12. Wilcox JN, Crocker IR, Scott NA, Robinson KA, King SB III, Waksman R. Mechanisms by which radiation may prevent restenosis: inhibition of cell proliferation and vascular remodeling. In: Vascular Brachytherapy, 2nd edition, pp127-138. Futura Publishing Co., Aramonk, NY, 1999. 13. Scott NA. Cardiovascular Disorders in African Americans. In: Essentials of Cardiovascular Medicine, 2nd edition (in press). 14. Wilcox JN, Scott NA. Adventitial remodeling associated with post-angioplasty restenosis. In: Vascular Brachytherapy, 3rd edition, Futura Publishing Co., Aramonk, NY, pp - , 2002. 15. Scott NA, Hampikian JM, Segal J. The RadioVascular Systems Catheter. In: Vascular Brachytherapy, 3rd edition, Futura Publishing Co., Aramonk, NY, pp - , 2002. ABSTRACTS (selected): 1. Scott NA, Verrier RL, Lown B, Wurtman RJ. Mechanisms mediating the influence of tyrosine on vulnerability to ventricular fibrillation. Clin Res 29:240A, 1981. 2. Lehnert H, Reinstein DK, Scott NA, Wurtman RJ. Tyrosine prevents tailshockinduced norepinephrine depletion in the locus coeruleus and behavioral depression in rats. Fed Proc 42:2795A, 1983. 13 3. Maisel AS, Gilpin EA, Ahnve S, Scott NA, Henning H, Ross J. Complex PVC's predict 1-year survival in non-Q-wave but not in Q-wave myocardial infarction. J Am Coll Cardiol 5:521, 1985. 4. Scott NA, Brown M. Hypotension following intra-artrial administration of a combination of neuropeptide Y and neuropeptide Y antisera. American Society of Hypertension Second Annual Meeting, May 17-20, 1987, New York, NY. 5. Boublik J, Scott N, Brown MR, Rivier J. Neuropeptide Y: Structure-activity relationships of D-substituted an N-terminally modified analogs. 10th American Peptide Symposium, May 23-28, 1987, St. Louis, MO. 6. Scott N, Webb V, Brown MR. Neuropeptide Y: Central nervous system effects of cardiovascular function. Society for Neuroscience Annual Meeting, November 16-21, 1987, New Orleans, LA. 7. Scott N, Maisel AS, Motulsky HJ, Brown MR. Elevated Neuropeptide Y levels in congestive heart failure with a blunted exercise response. Clinical Research 36 (3): 315A, 1988. 8. Boublik J, Scott N, Brown M, Rivier J. Neuropeptide Y; requirement of an intact, amidated C- terminus for in vivo hypertensive activity. 8th International Congress of Endocrinology, 1988. 9. Crum RL, Allen R, Scott NA, Ehlers R, Ward D, Bronsther O, Hansbrough J, Rivier J, Boublik J, Maisel A, Rockman H, Nicod P, Brown MR. Neuropeptide Y (NPY): measurements in human plasma. Endocrine Society Meetings, 1988. 10. Anderson H, Boublik J, Scott N, Brown M, Hagler A, Rivier J. Computer-assisted modeling suggests structural similarities between the snake "long" neurotoxins and neuropeptide Y and related peptides. Second Symp. of The Protein Society, San Diego, CA Aug. 13-17, 1988. 11. Scott NA, Boublik JH, Rivier JE, Brown MR. A Neuropeptide Y fragment decreases cardiac output and mean arterial pressure. Circulation 78: II-223, 1988. 12. Boublik JH, Scott NA, Brown MR, Rivier JE. Structure-Activity relationships for substantially truncated, C-terminal fragments of Neuropeptide Y with hypotensive activity in vivo. 9th Annual conference, Australian Neuroscience Society, Melbourne, Australia, Feb 6-8 1989. 13. Boublik J, Anderson H, Scott N, Brown M, Rivier J. Computer analysis suggests that members of the Neuropeptide Y family and the "long" snake toxins share structural similarities. 14th Annual Conference on Protein Structure and Function, Lorne, Australia. Feb 12-16, 1989. 14 14. Scott NA, Boublik JH, Rivier JE, Brown MR. Neuropeptide Y (NPY) decreases mean arterial pressure and cardiac output in passively immunized animals. New York Academy of Science Conference on the Central and Peripheral Significance of Neuropeptide Y and its related peptides. Baltimore MD, April 2-4, 1990. 15. Boublik JH, Spicer MA, Rivier JE, Scott NA, Brown MR. Neuropeptide Y: structure-activity relationships of synthetic analogs. Future Directions in Cardiovascular Research, September 4-6, 1990. 16. Martin TD, Martin SJ, Connolly MW, Scott NA, Gravanis MB. Takayasu's arteritis: aneurysmal disease without occlusive disease. American College of Chest Physicians, 1991. 17. Kern MA, Segal J, Ofili E, Heuser R, Scott NA, Aguirre F, St. Vrain J, Labovitz A. A new method for quantitating coronary collateral flow in patients during coronary angioplasty using the doppler guidewire. Circulation 84 (SupplI): II293, 1991. 18. Hearn JA, Douglas JS, Roubin GS, Ghazzal ZMB, Scott NA, King SB. Late outcome in patients receiving a balloon-expandable intracoronary stent for acute closure. Circulation 84 (SupplI): II-589, 1991. 19. Santoian EC, Gravanis MB, Anderberg K, Scott NA, Karas SP, Schneider JE, King SB. Use of a porous infusion balloon in swine coronary arteries: low pressure minimizes arterial damage. Circulation 84 (SupplI): II-591, 1991. 20. Scott NA, Weintraub WS, Carlin SF, Tao X, Hearn JA, Lembo NJ, Douglas JS, King SB. Acute closure during PTCA: Improved management with intracoronary stents, laser balloons and prolonged inflation. JACC 19: 93A, 1992. 21. Scott NA, Kelsey SF, Dingiloglu H, Detre K, Desvigne-Nickens P, Cowley MJ, King SB. PTCA in African-American patients: A review of the NHLBI registry. JACC 19: 139A, 1992. 22. Schneider JE, Gravanis MB, Santoian EC, Scott NA, Anderberg K, Cipolla G, King SB. Repeat balloon injury markedly increases smooth muscle cell proliferation and alters the pattern of intimal hyperplasia in a swine model of restenosis. JACC 19: 168A, 1992. 23. Schneider JE, Santoian EC, Gravanis MB, Cipolla GD, Tarazona N, Scott NA, King SB. Timing of repeat balloon injury influences intimal hyperplasia in a swine model of coronary restenosis. Society for Cardiac Angiography, 1992. 24. Santoian EC, Gravanis MB, Karas SP, Anderberg K, Scott NA, Schneider JE, King SB. Porous balloon infusion of high dose heparin does not inhibit intimal 15 hyperplasia in a normolipemic swine balloon injury model. Society for Cardiac Angiography, 1992. 25. Santoian EC, Gravanis MB, Karas SP, Schneider JE, Anderberg KA, Scott NA, Cipolla G, King SB. Sequence of the reparative phenomena and development of smooth muscle proliferation following coronary angioplasty in a swine restenosis model. Clin Res 40:364A, 1992. 26. Nunes GL, King SB, Hanson SR, Sahatjian RA, Scott NA. Hydrogel-coated PTCA balloon catheter delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation 86:II-380,1992. 27. Nunes GL, Hanson SR, Rowland SM, Juman I, Spaulding R, Robinson KA, Harker LA, Scott NA. A comparison of the thrombogenicity of stainless steel and tantalum coronary stents. Circulation 86:II-732, 1992. 28. Santoian EC, Schneider JE, Karas SP, Cipolla GD, Tarazona N, Scott NA, Robinson KA, Gravanis MB. Neointimal differences in swine coronary arteries after single balloon injury, balloon reinjury or stent injury. Circulation 86:II-801, 1992. 29. Deychak YA, Thompson MA, Rohrbeck SC, Mukherjee A, Herzog WR, Lundergan C, Scott N, Segal J. A Doppler guidewire used to assess coronary flow during directional coronary atherectomy. Circulation 86:I-22, 1992. 30. Robinson KA, Scott NA, Nunes GM. Comparison of stainless steel and tantalum as biomaterials for vascular stents. Scanning Microscopy 1992 Meeting, May 914, Chicago IL. 31. Nunes GL, Hanson SR, King SB III, Sahatjian RA, Barry JJ, Scott NA. Local heparin delivery with a hydrogel-coated PTCA balloon catheter inhibits plateletdependent thrombosis. J Am Coll Cardiol 21 (2): 117A, 1993. 32. Ghazzal ZMB, Hinohara T, Scott NA, Baim DS, Safian RD, Fishman N, King SB III. Directional coronary atherectomy in patients with recent myocardial infarction: A NACI Registry report. J Am Coll Cardiol 21 (2): 32A, 1993. 33. Nunes GL, Scott NA, Harker LA, King SB III, Hanson SR. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Soc for Cardiac Angiography and Interevntions, 1993. 34. Scott NA, Candal FJ, Robinson KA, Ades EW. Seeding of intracoronary stents with human endothelial cells. Circulation 88 (Suppl I): I-150, 1993. 16 35. Scott NA, Capers Q, Weintraub WS, Liberman HA, Morris DC, Douglas JS Jr., In hospital and long term outcome of PTCA in African-American women and men. Circulation 88 (Suppl I): I-449, 1993. 36. Scott NA, Weintraub WS, Liberman HA, Morris DC, Douglas JS Jr., King SB III. Outcome after acute closure syndrome following coronary angioplasty. Circulation 88 (Suppl I): I-299, 1993. 37. Wilcox JN, Scott NA, Lumsden AB, Subramanian RR, Rodriguez JC, Kelly AB. Onset of cell proliferation and growth factor expression after clinical angioplasty of primate vascular lesions. Circulation 88 (Suppl I): I-469, 1993. 38. Waksman R, Scott NA, Douglas JS Jr, Mays R, Yee-Petersen J, King SB III. Distal embolization is common after directional atherectomy in coronary arteries and vein grafts. Circulation 88 (Suppl I): I-299, 1993. 39. Robinson KA, Candal FJ, Scott NA, Ades EW. Seeding of vascular grafts with an immortalized human dermal microvascular endothelial cell line. American College of Angiology Annual Meeting, October 1993, Orlando FL. 40. Thomas CN, Barry JJ, King SB III, Scott NA. Local delivery of heparin with a PTCA infusion balloon inhibits platelet-dependent thrombosis. J Am Coll Cardiol 4A, 1994. 41. Thomas CN, Robinson KA, Cipolla GD, Jones M, King SB III, Scott NA. Invivo local delivery of heparin to coronary arteries with a microporous infusion catheter. J Am Coll Cardiol 484A, 1994. 42. Capers Q IV, Thomas CN, Weintraub WS, King SB III, Douglas JS Jr, Scott NA. Emergent stent placement: worse outcome in the patients with a recent myocardial infarction. J Am Coll Cardiol 71A, 1994. 43. Thomas CN, Capers Q IV, Frerichs FA, Petersen J, Douglas JS Jr, Ghazzal ZMB, King SB III, Scott NA. Clinical outcome in stenting following acute versus threatened closure. Clinical Research 1994. 44. Hanson SR, Wilcox JN, Kelly AB, Lumsden AB, Scott NA, Harker LA. Thrombin mediation of arterial smooth muscle cell proliferation after mechanical injury in non-human primates. Blood 80(suppl 1): 166A, 1992. 45. Waksman R, Ghazzal ZMB, Fernandez A, Scott NA, Douglas JS Jr. Efficacy and Safety of using perfusion dilatation catheter as initial balloon in coronary angioplasty. Washington D.C. Feb 24-27, 1994. 17 46. Scott NA, Ross CE, Subramanian RR, Martin F, Simonet L, Wilcox JN. Characterization of the Cellular Response to Coronary Injury. Circulation 90 (Suppl I): I-392, 1994. 47. Robinson KA, Waksman R, Thomas C, Sigman SR, Cipolla GD, Rowland S, Jones M, Scott NA, King SB III. Transfer of Microparticles to Balloon-injured Swine Coronary Arteries Using the Microporous Infusion Catheter. JACC. 5A, February 1994. 48. Wilcox JN, Scott NA, Subramanian RR, Ross CE, Adams-Burton CR, Stoltenborg JK, Corjay MH. A Potential Role for BTG1, an Anti-Proliferative Gene, in the Control of Cell Proliferation After Angioplasty of Porcine Coronary Arteries. Circulation 92 (Suppl I): I-34, 1995. 49. Scott NA, Ross CE, Wilcox JN. The Relationship Between Cellular Proliferation and Thrombus Formation After Balloon Oversterch Angioplasty of Porcine Coronary Arteries. Circulation 92 (Suppl I): I-111, 1995. 50. Weintraub WS, Ghazzal ZMB, Scott NA, Douglas Jr JS, Benard J, Mauldin P, Becker E, King SB III. Declining Resource Utilization in Interventional Cardiology. JACC. 81A, February 1995. 51. Waksman R, Rodriguez JA, Robinson KA, Scott NA, Crocker IR, Ross CE, Wilcox JN. Intracoronary Radiation Affects Restenosis in the Swine Model by Reduction of Cell Proliferation and Favorable Remodeling. Circulation 94 (Suppl I): I-108, 1996. 52. Waksman R, Shen Y, Ghazzal Z, Scott NA, Douglas JS Jr, King SB III. Optimal Balloon Inflation Pressures for Stent Deployment and Correlates of Stent Thrombosis and In-Stent Restenosis. Circulation 94 (Suppl I): I-258, 1996. 53. Oshinski JN, Dixon WT, Trudeau J, Hofland L, Scott NA, Pettigrew RI. Navigator Echo Gating Improves Coronary MRA. Circulation 94 (Suppl I): I417, 1996. 54. Waksman R, Robinson KA, Scott NA, Crocker IR, King SP III, Ross CE, Cipolla GD, Wilcox JN. Endovascular Radiation Reduces Vascular Lesion Formation After Balloon Injury of Pig Coronary Arteries by Inhibiting Cell Proliferation. JACC. 14A, February 1996. 55. Okamoto E, Couse TL, Goodman RB, Scott NA, Wilcox JN. Perivascular Inflammation after Balloon Angioplasty of Porcine Coronary Arteries. Circulation 100 (18 Suppl 2): 607, 2000. 18 56. Scott NA, Powers N, Shih LB, Harris S, Peters D, Segal J. Local Delivery of Paclitaxel with an Iontophoretic Catheter Prevents Neointimal Proliferation after Coronary Injury and Stent Placement. Amer J Cardiol 92 (6 Suppl 1), 2003. 57. Scott NA, Powers N, Shih LB, Harris S, Peters D, Segal J. Local Delivery of E2F Decoy with an Iontophoretic Catheter Prevents Neointimal Proliferation after Stent Placement. Amer J Cardiol 92 (6 Suppl 1): 95L, 2003. 58. Segal J, Peters D, Shen N, Shih LB, Scott NA. A New Iontophoretic Catheter for Treatment of Hemodialysis Graft Stenosis. Amer J Cardiol 92 (6 Suppl 1), 2003. 59. Whitbourn RJ, Turovskiy R, Liu J, Pandya S, Scott NA. First in Man Clinical Experience with the CardioMind 0.014” Sparrow™ Drug Eluting Coronary Stent System. Amer J Cardiol 102 (Issue 8), October 2008. 60. Scott NA, Harris S, Burkoth T, Powers N, Segal J. Intracoronary Paclitaxel Delivery with a Novel Mesh Catheter. Amer J Cardiol 2009 (in press). 19